Life Science, RNAi, Patents
Alnylam to Receive European Patent
Ryan McBride 4/20/09
Alnylam Pharmaceuticals (NASDAQ:ALNY), a Cambridge, MA-based developer of RNA-interference (RNAi) drugs, says that the European Patent Office will grant the firm a patent related to its “Tuschi I” patent series covering the use of double-stranded RNA molecules for RNA-interference. The patent, which the company expects to be issued in four months, covers claims such as the use of RNAi to reduce expression of a gene with double-stranded RNA molecules of 21 to 23 nucleotides in length.
Ryan McBride is Xconomy's correspondent. You can reach him at rmcbride@xconomy.com, or follow him on Twitter at http://twitter.com/Ryan_McBride.
